LYMPHIR
Growthdenileukin diftitox-cxdl
BLAINJECTIONINJECTABLE
Approved
Aug 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
LYMPHIR (denileukin diftitox-cxdl) is diftitox-cxdl is a fusion protein designed to direct the cytocidal action of diphtheria toxin (dt) to cells which express the il-2 receptor. First approved in 2024.
Drug data last refreshed Yesterday
Mechanism of Action
diftitox-cxdl is a fusion protein designed to direct the cytocidal action of diphtheria toxin (DT) to cells which express the IL-2 receptor. After uptake into the cell, the DT fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death. Denileukin diftitox-cxdl…
Pharmacologic Class:
CD25-directed Cytotoxin
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.